Lesson plan

Ψ-2C-DFMO

Ψ-2C-DFMO, also known as ψ-2C-O-35 or as 4-difluoromethoxy-2,6-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and ψ-phenethylamine families. It is the phenethylamine (α-demethyl) analogue of ψ-DODFMO and is also structurally related to other psychedelics like difluoromescaline (DFM) and 2C-T-35 (2C-T-DFM). The drug has been found to be active at a dose of 17 mg orally, with moderately intense effects and a relatively long duration of around 18 hours. Ψ-2C-DFMO was first described in the scientific literature by Daniel Trachsel in 2012. It is a controlled substance in Canada under phenethylamine blanket-ban language.

Back to article

Article summary

Ψ-2C-DFMO, also known as ψ-2C-O-35 or as 4-difluoromethoxy-2,6-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and ψ-phenethylamine families. It is the phenethylamine (α-demethyl) analogue of ψ-DODFMO and is also structurally related to other psychedelics like difluoromescaline (DFM) and 2C-T-35 (2C-T-DFM). The drug has been found to be active at a dose of 17 mg orally, with moderately intense effects and a relatively long duration of around 18 hours. Ψ-2C-DFMO was first described in the scientific literature by Daniel Trachsel in 2012. It is a controlled substance in Canada under phenethylamine blanket-ban language.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.